A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia
- 30 April 2012
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 125 (1), 136-140
- https://doi.org/10.1016/j.ygyno.2011.11.042
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium TrialUrology, 2010
- Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2010
- A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II ConsortiaGynecologic Oncology, 2010
- Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II studyGynecologic Oncology, 2009
- Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trialGynecologic Oncology, 2008
- Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II studyGynecologic Oncology, 2008
- Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) StudyGynecologic Oncology, 2004
- Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomasInternational Journal of Gynecologic Cancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000